REGENERON PHARMACEUTICALS, INC. REGN Cash Flow

Regeneron pharmaceuticals, inc. (REGN)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Dec'10	Sep'10	Jun'10	Mar'10
Cash flows from operating activities:
Net Income (Loss) Attributable to Parent
2,279,300	2,115,800	2,144,200	2,069,200	2,427,500	2,444,400	1,797,508	1,591,225	1,427,569	1,198,500	1,278,085	1,154,572	963,046	895,500	797,401	742,995	741,420	636,056	571,157	444,134	345,842	338,126	334,213	392,144	383,169	413,738	797,963	848,125	837,492	750,269	226,419	-27,414	-166,662	-221,760	-182,914	-154,424	-117,393	-104,468	0	0	0
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization
215,400	210,300	198,800	181,300	162,800	148,200	139,940	142,259	143,785	145,500	139,815	129,935	119,838	104,700	98,755	91,590	81,859	74,909	66,134	59,465	57,183	52,686	49,843	46,641	43,327	41,204	39,690	38,216	37,931	36,940	35,088	34,035	32,520	31,082	29,242	25,860	22,482	19,687	0	0	0
Non-cash compensation expense
462,200	464,300	457,500	451,900	452,900	427,400	427,856	441,453	455,911	507,300	534,724	541,006	551,439	559,900	563,712	534,974	497,540	459,049	413,675	379,153	349,724	321,750	280,892	258,517	238,132	215,377	173,989	148,780	123,943	94,157	78,918	71,747	64,537	56,094	54,127	49,553	45,864	39,897	0	0	0
Other non-cash items, net
-77,100	29,300	-208,000	-177,700	7,500	-12,100	63,216	29,031	-55,344	-63,500	-75,530	-74,936	-45,099	-45,100	-31,229	-27,340	-47,711	-52,562	-84,017	-103,990	-82,618	-77,571	-59,514	-35,026	-43,338	-46,751	-36,123	-41,316	-38,729	-34,049	-18,229	-16,938	-8,626	-6,714	0	0	0	-	-	-	-
Non-cash interest expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	23,232	23,049	23,163	22,925	0	0	0	-	-	-	-	43	0	0	0
Loss on Extinguishment of Debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred taxes
110,000	130,600	216,500	249,800	144,300	140,000	-393,542	-361,037	-353,388	-318,800	278,015	255,185	321,303	360,100	245,975	225,206	164,152	121,623	85,090	93,253	84,771	53,276	-110,924	-135,625	-95,959	-62,195	423,046	432,678	379,681	340,156	0	0	0	-	-	-	-	-	-	-	-
Changes in assets and liabilities:
Increase in Sanofi, trade, and other accounts receivable
551,000	473,100	501,200	460,800	390,400	268,900	231,471	194,673	194,372	362,700	327,550	92,549	-115,700	143,800	204,557	356,846	559,103	491,421	551,512	538,456	272,144	34,927	-158,979	-45,453	220,219	245,472	440,971	462,202	570,868	588,398	524,287	352,325	152,113	21,118	-4,134	-10,972	15,545	17,518	0	0	0
Increase in inventories
347,700	335,500	333,500	374,000	357,700	387,900	360,155	344,756	333,256	314,200	285,739	228,456	157,281	149,800	145,277	139,122	168,654	111,825	72,284	65,243	46,831	56,947	62,131	54,107	45,925	47,956	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Decrease in prepaid expenses and other assets
114,600	130,400	-53,300	72,600	70,200	55,700	172,891	-23,268	24,175	113,300	26,966	98,154	23,485	-36,100	31,396	56,232	83,650	79,476	29,700	-17,961	-19,005	45,327	25,017	24,575	-4,488	-7,571	-49,611	3,154	36,525	25,371	68,057	14,433	11,608	-6,612	8,233	8,288	-5,830	8,212	0	0	0
Increase in deferred revenue
286,800	294,000	210,800	290,800	-58,900	-194,500	-83,484	-186,645	-180,000	-113,100	-96,992	167,795	165,495	244,300	267,005	691,427	707,554	608,892	612,194	-41,193	-52,967	-8,403	-17,215	-13,812	2,081	-41,496	-33,287	-34,987	-38,421	-41,077	-36,436	-37,444	-39,145	-40,329	-47,007	120,981	144,328	158,151	0	0	0
(Decrease) increase in accounts payable, accrued expenses, and other liabilities
33,500	444,500	150,000	253,300	459,100	210,000	185,608	191,032	-134,195	-23,200	117,654	-27,157	338,264	254,000	246,443	308,244	376,971	303,657	249,328	273,700	205,438	161,182	118,296	117,912	90,440	136,684	76,642	13,782	30,374	10,979	43,993	44,228	49,152	50,016	14,861	28,077	8,536	7,605	0	0	0
Total adjustments
-48,300	314,200	227,200	197,800	45,800	-249,300	235,729	403,944	142,430	108,600	-147,539	212,171	833,766	590,400	579,939	876,169	736,076	694,724	675,975	74,466	251,339	414,309	501,776	371,979	172,706	174,858	-397,911	-542,910	-738,818	-824,884	-444,536	-235,056	-51,481	80,078	50,698	230,444	215,613	203,690	0	0	0
Net cash provided by operating activities
2,231,000	2,430,000	2,371,400	2,267,000	2,473,300	2,195,100	2,033,237	1,995,169	1,569,999	1,307,100	1,130,546	1,366,743	1,796,812	1,485,900	1,377,340	1,619,164	1,477,496	1,330,780	1,247,132	518,600	597,181	752,435	835,989	764,123	555,875	588,596	400,052	305,215	98,674	-74,615	-218,117	-262,470	-218,143	-141,682	-132,216	76,020	98,220	99,222	0	0	0
Cash flows from investing activities:
Purchases of marketable and other securities
2,876,500	3,202,400	3,146,800	2,853,400	2,284,400	1,845,500	1,927,052	1,980,992	1,669,806	1,277,200	1,086,995	1,057,866	1,018,094	809,400	613,116	445,203	461,330	557,105	635,894	530,523	406,085	564,188	578,402	669,144	649,920	577,278	550,004	482,681	603,612	470,945	523,106	495,660	273,322	240,391	478,997	398,594	443,168	605,124	0	0	0
Sales or maturities of marketable securities
1,707,000	1,604,200	1,437,900	1,059,300	858,700	775,600	809,425	734,634	680,888	544,600	461,684	444,489	333,103	274,500	253,533	235,845	307,390	327,437	525,934	514,336	474,404	476,417	275,472	226,752	405,861	378,146	497,591	574,572	418,110	439,209	362,596	381,606	444,090	426,356	369,770	353,643	267,906	273,723	0	0	0
Purchase of restricted cash and marketable securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	110	65	772	277	0	0	0	-	-	-	-
Capital expenditures
525,400	429,600	376,100	360,600	378,000	383,100	405,237	358,690	301,539	272,600	315,377	374,280	458,267	511,900	539,265	566,808	667,865	677,933	617,696	551,366	382,346	333,006	284,440	236,362	199,942	156,323	102,509	81,066	59,485	49,337	45,464	44,114	46,106	57,217	78,190	91,395	99,112	99,689	0	0	0
Net cash used in investing activities
-1,694,900	-2,027,800	-2,085,000	-2,164,700	-1,813,700	-1,463,000	-1,532,864	-1,605,048	-1,290,457	-1,005,200	-940,688	-987,657	-1,143,258	-1,046,800	-898,848	-776,166	-821,805	-907,601	-727,656	-567,553	-314,027	-420,777	-587,370	-678,754	-444,001	-355,455	-154,404	11,294	-244,524	-81,073	-206,084	-158,233	123,890	128,471	-192,243	-141,168	-280,283	-437,031	0	0	0
Cash flows from financing activities:
Proceeds in connection with capital and facility lease obligations
-	-	-	-	-	-	-	-	-	-	57,015	62,100	62,100	5,100	6,053	593	20,635	27,373	26,120	26,219	5,905	-1,095	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Payments in connection with capital and facility lease obligations
-	-	-	-	-	-	-	-	-	19,900	50,872	51,512	45,063	32,800	0	0	0	-	-	-	-	-	-	-	-	-	2,227	2,186	2,352	2,203	2,258	1,977	1,861	1,667	2,038	1,732	1,334	1,028	0	0	0
Payments in connection with facility lease obligation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Repayments of Convertible Debt
-	-	-	-	-	-	-	-	-	-	-	-	-	12,900	33,110	35,116	151,520	166,467	305,521	303,515	237,325	220,639	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments for Repurchase of Warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	643,400	292,117	691,073	691,073	573,487	674,998	276,042	419,083	294,552	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of Common Stock
882,600	211,800	190,600	235,500	241,700	114,500	100,708	85,607	236,927	240,200	263,815	251,787	104,069	126,700	145,712	154,139	169,389	206,358	195,664	178,813	147,276	126,045	96,479	86,150	99,471	57,393	56,827	58,218	44,685	63,549	51,892	54,717	61,009	43,587	226,963	217,025	205,768	200,588	0	0	0
Payments in connection with Common Stock tendered for employee tax obligations
332,400	188,000	150,600	195,800	197,900	187,200	0	0	0	-	-	-	-	143,200	135,818	169,620	140,387	160,537	163,391	238,524	225,690	267,584	204,595	186,940	255,088	195,087	258,183	174,993	117,307	163,300	80,237	81,813	73,093	25,078	0	0	0	-	-	-	-
Repurchases of Common Stock
586,600	275,900	29,400	14,400	14,400	4,400	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Excess Tax Benefit from Share-based compensation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	405,317	410,683	452,421	491,812	439,278	448,215	439,608	326,876	211,909	102,148	12,184	6,601	4,308	0	0	0	-	-	-	-	-	-	-	-
Net cash provided by financing activities
-36,400	-252,100	10,600	25,300	29,400	-77,100	-204,635	-216,531	-71,812	-24,400	-305,653	-268,782	-433,496	-700,500	-212,720	-587,044	-559,384	-262,796	-511,443	-160,628	-237,105	-218,547	134,724	133,091	169,622	72,191	-101,435	-106,777	-68,373	-97,646	336,804	338,334	353,462	384,249	205,568	207,460	200,128	243,306	0	0	0
Net increase in cash, cash equivalents, and restricted cash
499,700	150,100	297,000	127,600	689,000	655,000	295,738	173,590	207,730	277,500	-115,795	110,304	220,058	-261,400	265,772	255,954	96,307	160,383	8,033	-209,581	46,049	113,111	383,343	218,460	281,496	305,332	144,213	209,732	-214,223	-253,334	-87,397	-82,369	259,209	371,038	-118,891	142,312	18,065	-94,503	0	0	0